

NLM Citation: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Terazosin.

[Updated 2018 Dec 3].

Bookshelf URL: https://www.ncbi.nlm.nih.gov/books/



Terazosin

Revised: December 3, 2018.

CASRN: 63590-64-7

Drug Levels and Effects

Summary of Use during Lactation

Because no information is available on the use of terazosin during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site .

Effects on Lactation and Breastmilk

Relevant published information in nursing mothers was not found as of the revision date. However, the pharmacologically similar drug prazosin does not affect serum prolactin concentration in patients with hypertension.[1][2] The prolactin level in a mother with established lactation may not affect her ability to breastfeed.

References

- 1. Barbieri C, Caldara R, Ferrari C et al. Metabolic effects of prazosin. Clin Pharmacol Ther. 1980;27:313-6. PubMed PMID: 6102000.
- 2. Barbieri C, Ferrari C, Borzio M et al. Metabolic effects of chronic prazosin treatment. Horm Metab Res. 1980;12:331-4. PubMed PMID: 6105121.

Substance Identification

Substance Name

Terazosin

CAS Registry Number

63590-64-7

Drug Class

Breast Feeding

Lactation

Adrenergic alpha-Antagonists

Antihypertensive Agents